drug pricing policy

Business news, market intelligence, and global industry analysis.

The Latest

Volex (AIM: VLX) upgrades FY2026 revenue to at least $1.22bn as AI data centre demand doubles and board eyes Main Market move

Boliden AB (STO: BOL) warns Garpenberg seismic damage will cut 2026 output and hit Q1 EBITDA

Can inhaled nintedanib improve tolerability and adherence in IPF treatment, according to Avalyn Pharma Inc.?

Representative image of a motorway corridor and capital flows illustrating HICL Infrastructure PLC’s £311 million A63 Motorway stake sale in France, as the London-listed infrastructure investor exits the Atlandes asset at a 21% premium to book value.

HICL Infrastructure (LSE: HICL) to sell A63 Motorway stake for £311m at 21% premium to book value

AstraZeneca Posts 10% Revenue Growth in Q1 2025 as Oncology Pipeline and R&D Deals Signal Long-Term Upside

AstraZeneca strikes $50bn U.S. deal to lower drug prices while reshoring manufacturing amid tariff freeze

AstraZeneca inks $50B U.S. deal to cut drug prices and boost onshore manufacturing. See what this means for patients, profits, and pharma’s policy future.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

October 13, 2025